Document Classification

Section Type: RESULTS

Text: Any-grade adverse events that were more common (10 % difference) with axitinib than with sorafenib were diarrhoea (94 [50 %] of 189 patients vs 38 [40 %] of 96 patients), hypertension (92 [49 %] vs 28 [29 %]), weight decrease (69 [37 %] vs 23 [24 %]), decreased appetite (54 [29 %] vs 18 [19 %]), dysphonia (44 [23 %] vs ten [10 %]), hypothyroidism (39 [21 %] vs seven [7 %]), and upper abdominal pain (31 [16 %] vs six [6 %]) ; those more common with sorafenib than with axitinib included palmar-plantar erythrodysaesthesia (PPE ; 37 [39 %] of 96 patients vs 50 [26 %] of 189), rash (19 [20 %] vs 18 [10 %]), alopecia (18 [19 %] vs eight [4 %]), and erythema (18 [19 %] vs five [3 %]).